Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus(®)): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial

INTRODUCTION: LY2963016 insulin glargine (LY IGlar), a biosimilar of Lantus® insulin glargine (IGlar), demonstrated comparable efficacy and safety versus the reference product in Chinese patients with type 1 diabetes mellitus (T1DM) in the randomized, phase III ABES trial. This post hoc analysis aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Xiang, Feng, Chen, Lou, Ying, Zhou, Zhiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174415/
https://www.ncbi.nlm.nih.gov/pubmed/35471721
http://dx.doi.org/10.1007/s13300-022-01262-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174415/
https://www.ncbi.nlm.nih.gov/pubmed/35471721
http://dx.doi.org/10.1007/s13300-022-01262-8

Ejemplares similares